Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer

Detalles Bibliográficos
Autores principales: Watanabe, Satomi, Takeda, Masayuki, Otani, Tomoyuki, Yoshida, Takeshi, Sakai, Kazuko, Olek, Elizabeth, Rothenberg, S. Michael, Kherani, Jennifer, French, Pearl P., Nishio, Kazuto, Ito, Akihiko, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
CASE REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140803/
https://www.ncbi.nlm.nih.gov/pubmed/34036231
http://dx.doi.org/10.1200/PO.20.00282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140803/
https://www.ncbi.nlm.nih.gov/pubmed/34036231
http://dx.doi.org/10.1200/PO.20.00282

Ejemplares similares